Margarida Geraldes

TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

TL;DR: The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events as mentioned in this paper.

TL;DR: In this paper, a simple randomized adaptive design is proposed for estimating the difference between two success probabilities and the difference of two normal means, where the optimal proportion of the data that should be allocated to the first population, if it exists, often depends on unknown parameters.

TL;DR: In this article, the doubly adaptive weighted differences design, which gives an explicit weight to each of the goals, is introduced and its theoretical properties are investigated and simulation results which assess the proportion of successes and the mean square error of estimators are given.

TL;DR: Five Pharmaceutical Research and Manufacturers Association (PhRMA) companies recently performed retrospective analyses of placebo and nondrug 12-lead resting electrocardiogram (ECG) data from five rigorously conducted studies in which the collection and analysis of QT/QTc intervals was a primary objective.